Gilead and MacroGenics to develop bispecific cancer antibodies
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
List view / Grid view
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
22 October 2015 | By Victoria White
Trial startup activities are underway and MacroGenics expects to begin enrolling patients by the first quarter of 2016...